Medical Device News Magazine

Breakthrough Study Published Measuring the Effect of EOTTS to Reduce Medial Knee Compartment Forces

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

GraMedica, and the research team of Dr. Lukas Kolodziej, Dr. Rodney K. Summers and Dr. Michael E. Graham, is pleased to announce a groundbreaking study showing how Extra-Osseous Talotarsal Stabilization (EOTTS) can substantially reduce or possibly eliminate a leading cause of knee misalignment and arthritis.

GraMedica reports, the first of its kind, the study measured the in vivo forces acting within the medial knee compartment, before and after EOTTS. Millions of people suffer from chronic knee pain and every year that number continues to grow. Typically treatments are focused on pain relief or localized surgery to the knee. Pain relief does not eliminate or reduce the cause of knee pain. The results of conservative care, and even knee surgery, provide temporary relief; and these patients continue to have pain, or eventually have a recurrence of pain. What the research team found had been often overlooked in the treatment of knee pain, was misaligned feet.

Hindfoot misalignment, or talotarsal joint (TTJ) instability, occurs when the ankle bone partially dislocates on the heel bone. The naturally occurring space between the two bones, the sinus tarsi, should always be “open” just like an artery that carries blood throughout the body. While the link behind ankle bone displacement and knee pain is already known, the issue has been how to realign the ankle bone while still allowing a normal range of motion. With the development of an EOTTS stent – a titanium spacer called HyProCure® – that is placed into the sinus tarsi, the ankle and heel bones are instantly stabilized and realigned.

“The primary goal of knee treatment has always been to provide better stability and alignment. Failure to achieve that treatment goal leads to continued tissue stress on the knee, and continued pain,” says Dr. Kolodziej, the lead researcher in the study. “Many patients have claimed significant relief with their knee pain after the insertion of a type II EOTTS stent and we are pleased that this study confirms the importance of realigning and stabilizing the hindfoot for the prevention and treatment of chronic knee pain.”

The research from this study confirmed that ankle bone displacement leads to increased forces on the inner knee, the most common area of knee joint arthritis. The insertion of the HyProCure® titanium spacer/stent reduced the pressure by nearly 33%. This is the very first treatment that has shown this kind of reduction of pressure.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”